Actua Announces Second Quarter 2017 Financial Results
Aug 09, 2017 12:31 pm UTC| Business
RADNOR, Pa., Aug. 09, 2017 -- Actua Corporation (Nasdaq:ACTA) (“Actua”) today reported its results for the second quarter ended June 30, 2017. “We are pleased with the results we achieved in the second quarter,” said...
Tyme Inc. Appoints Dr. Jonathan Eckard as Chief Scientific Affairs Officer
Aug 09, 2017 12:30 pm UTC| Business
NEW YORK, Aug. 09, 2017 -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced the appointment of Jonathan Eckard,...
New Research Supports Think Tank Assertions on Cyber Resilience Planning
Aug 09, 2017 12:30 pm UTC| Business
WATERTOWN, Mass., Aug. 09, 2017 -- Mimecast Limited (NASDAQ:MIME), a leading email and data security company, today announced it published the e-book, Strengthen Your Defenses Against Cybercrime: Cyber Resilience...
Gulf Resources Announces Conference Call to Discuss Second Quarter Year 2017 Results
Aug 09, 2017 12:30 pm UTC| Business
SHOUGUANG, China, Aug. 09, 2017 -- Gulf Resources, Inc. (Nasdaq:GURE) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced that the...
Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI)
Aug 09, 2017 12:30 pm UTC| Business
Key Highlights Final approval for key first in-human Clinical Study for CDI treatment, by Israeli Ministry of HealthAn estimated 28,000 patients die each year from CDI infections in the USA aloneStudy of 60 CDI patients...
Aug 09, 2017 12:30 pm UTC| Business
EMERYVILLE, Calif., Aug. 09, 2017 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the closing of the second and final tranche of its previously announced financing. The second tranche...
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results
Aug 09, 2017 12:30 pm UTC| Business
RESULT, pivotal Phase 3 study of Sollpura began screening patients in the U.S. and EuropeRESULT study approved by the Cystic Fibrosis Foundation Therapeutics Development NetworkBRIGHT, Phase 2 study of blisibimod in IgA...